Slides
Page 1
Draŷ v4 Annual General Meeting 2026 4 November 2026 From a proven product, to a multi-plaŹorm leader.
Page 2
A strongly independent Board with diverse skills Steven Sargent BBus, FAICD, FTSE Independent Non-executive Director and Chairman Michael Kavanagh BSc, MBA (Advanced) CEO, President and Managing Director Marie McDonald BSc (Hons), LLB (Hons), FAICD Independent Non-executive Director Sarah Butler BA(Hons), MA, Adjunct Professor, FAICD Independent Non-executive Director Tracey Baźen MBBS, MBA (Harvard), FAICD, MHA, FRACMA Independent Non-executive Director Larry Marshall BSc (Hons), PhD, FAICD, FTSE, FAIP, Federation Fellow Independent Non-executive Director Gerard Dalbosco M.AppFin, B.Comm, FCA, FFIN, GAICD Independent Non-executive Director 2
Page 3
How to ask a question •To ask a wriźen question, select the Q & A icon. •Select the topic your question relates to from the drop-down list. •Type your question in the text box and press the send icon. •To ask a verbal question follow the instructions below the broadcast window. 3
Page 4
How to vote •When the poll is open, select the vote icon at the top of the screen •To vote, select either For, Against or Abstain •You will see a vote confirmation •To change or cancel your vote “click here to change your vote” at any time until the poll is closed 4
Page 5
Steve Sargent Non-executive Director and Chairman 5
Page 6
Delivering trusted care Shaping global standards Out-engineering infection risk Our focus is infection prevention, for life Our mission is to improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted by introducing innovative technologies that deliver improved standards of care. patients protected in FY26
Page 7
Evolving infection prevention environment Leveraging its expertise in automation, medical reprocessing and digitisation, Nanosonics is leading the way to support healthcare providers to protect more patients. Technology advancements Expanding clinical applications Hospital budget pressures & inflation Contamination risk reduction Cybersecurity INFECTION PREVENTION DYNAMICS Driving solutions that are Safer for patients Automated & workflow efficient More effective & validated Digital & safe Compliant & audit-ready 7
Page 8
88 trophon business model & performance Creates opportunities for tomorrow Growing revenue & EBIT in constant currency Disciplined capital allocation Improving operating leverage Strong cash generation High return on capital in trophon-only business Product growth & expansion CORIS commercialisation Market expansion Driving value creation Nanosonics is entering a defining period of growth
Page 9
Our commitment to sustainability Caring for our customers and their patients, our partners, our people, the planet and the community. reduction in Scope 1 and 2 emissions in FY26 80% reduction over the past 2 years Five areas of focus 9
Page 10
A strongly independent Board with diverse skills Steven Sargent BBus, FAICD, FTSE Independent Non-executive Director and Chairman Michael Kavanagh BSc, MBA (Advanced) CEO, President and Managing Director Tracey Baźen MBBS, MBA (Harvard), FAICD, MHA, FRACMA Independent Non-executive Director Larry Marshall BSc (Hons), PhD, FAICD, FTSE, FAIP, Federation Fellow Independent Non-executive Director Gerard Dalbosco M.AppFin, B.Comm, FCA, FFIN, GAICD Independent Non-executive Director 10Sarah Butler BA(Hons), MA, Adjunct Professor, FAICD Independent Non-executive Director Marie McDonald BSc (Hons), LLB (Hons), FAICD Independent Non-executive Director
Page 11
Newly announced independent Non-executive Board member Julien Sauvagnargues Independent Non-executive Director Joining the Nanosonics Board on 1 December 2026 •Global MedTech executive •Two decades at Olympus •European and North American experience •Commercial, growth and operational experience 11
Page 12
Michael Kavanagh CEO, President and Managing Director Building the future of automated infection prevention 12
Page 13
Led by an experienced team Michael Kavanagh BSc, MBA (Advanced) CEO, President and Managing Director Jason Burriss BCom, CA Chief Financial Officer Kimberly Hill BSc Chief Marketing Officer & Regional President, Asia Pacific Jon Burdach, BBioMedSc (Hons), PhD Chief Medical Affairs & Scientific Officer Maźhew Carbines LLB, Bcom General Counsel & Company Secretary Sunny Pillai MBA, BEng(Hons) Chief Information Officer Jodi Sampson MBA(Exec), CPHR, MAICD Chief People and Culture Officer Derek Minihane BSEE, JD Chief Technology Officer Bill Haydon BA, MBA Regional President, North America Ronan Wright BSc, Bus Management, Beng Regional President, Europe Middle East & Africa Rod Lopez MBA, BEng (Hons), GAICD Chief Operating Officer 13
Page 14
FY26: underlying growth, disciplined execution A strong core business continued to fund investment in the next plaŹorm. $203.9m reported revenue 3% growth $211.5m revenue at CC 6% growth 76.9% gross margin 77.6% at CC $21.6m EBIT at CC 21% growth $155.2m cash no debt Core franchise strength 4,230 trophon placements, up 9%. The installed base grew 6% to 39,230 devices. Investment with discipline $31.8m invested in R&D while total operating expense of $141.4M was held to 2% growth. Capital flexibility $13.6m business cash flow excluding the FY26 buy back, with balance sheet capacity to fund growth. FY26 delivered continued trophon growth while investing in the next phase of expansion. 14
Page 15
Core trophon-only business profitability growing strongly Generating cash and funding next plaŹorm growth. Sustained EBIT growth and high-quality cash conversion in the trophon-only business demonstrates durability and provides self-funded capacity for the next phase of growth. $50.6M 5% on pcp EBIT $56.5M 16% CC EBIT in CC
Page 16
FY26 delivery positioned Nanosonics for its next phase Disciplined operational execution laid the foundations for the next phase of growth TROPHON trophon3 and trophon2 Plus launched; adoption accelerated in the second half. CORIS Clearances across Australia, Europe and the UK; first expanded US indication cleared. OPERATIONS US consumables manufacturing established and Australian CORIS device manufacturing readied. DIGITAL Connectivity and traceability capabilities expanded to deepen customer workflow value. FY26 delivered key operational milestones to support the next phase of growth. 16
Page 17
Gross Profit % Revenue Nanosonics reaffirms FY27 guidance $220 million to $228 million, reflecting 8% to 12% growth on FY26. FY27 guidance at constant currency 74%-76% Operational expenses $156 million to $163 million, reflecting 10% to 15% growth on FY26. Guidance is at constant currency, using a USD/AUD exchange rate of 0.68. Nanosonics generates the majority of its revenue in USD. If the Revenue range in the above table were recast using an average exchange rate for USD/AUD of 0.71 FY27 , rather than constant currency, and the hedging program is taken into account, the Revenue range would be approximately $3 million lower. Guidance assumes no changes to the global trading environment and US tariffs at current level of 12.5%. All guidance is subject to uncertainty in relation to potential impacts associated with macroeconomic and political uncertainty, as well as potential impacts from increased competitive activity in the USA. Q1 FY27 performance is consistent with Nanosonics’ expectations. 17
Page 18
From a successful single-plaŹorm company to a repeatable plaŹorm company Build from trophon. trophon PROVEN CORE Scale CORIS. CORIS SECOND PLATFORM Repeat our capability selectively. FUTURE PLATFORMS 18
Page 19
The opportunity is to automate what healthcare still performs manually Manual variability, fragmented records and workforce pressure create a broad class of problems to solve. AUTOMATE Replace technique-dependent work with automated workflows STANDARDISE Deliver repeatable performance across people and sites VALIDATE Make outcomes measurable, defensible and audit-ready CONNECT Create cycle-level traceability and workflow insight A focused strategic space with room for multiple plaŹorms
Page 20
The capability system to deliver our growth strategy Integrated expertise supports each plaŹorm from clinical need through to commercial scale. R&D + engineering - PlaŹorm, product, soŷware and consumablesClinical + medical – Need definition, evidence and adoptionBioscience – biological models and testingManufacturing + supply - Devices, consumables and resilient scaleDigital + connectivity - Traceability, insight and workflow dataCommercial + service - Implementation, training and lifecycle supportRegulatory + quality - Global clearances and validated systems20
Page 21
CAPITAL REVENUE 01 New installed base device sales, trophon3 02 Upgrade capital sales 03 Capital soŷware upgrades, trophon2 Plus RECURRING REVENUE 04 Core consumables 05 Ecosystem consumables 06 Service 07 Connectivity subscriptions trophon still has a substantial runway for profitable growth The plaŹorm can compound through installed base, upgrades, utilisation and lifetime value. More devices × more utilisation × more ecosystem value × more upgrades and service. Geographic expansion opportunity remains beyond current markets. 39,230 installed base 6% FY26 growth 8,000 EPR upgrade opportunity remaining in North America $149.2m recurring revenue FY26 reported $50.6m trophon-only EBIT 16% CC growth 21
Page 22
Nanosonics CORIS® System. A new era in flexible endoscope reprocessing starts here.
Page 23
A critical cleaning step, manual methods cannot reliably complete Cleaning is the critical first step in reprocessing flexible endoscopes, yet it remains manual, variable and unverified. The CORIS System automates it. THE PROBLEM Manual cleaning cannot reach every channel Unreachable channels Narrow and branched channels are difficult or impossible to brush and flushing alone may not remove contamination. Biofilm persists Contamination and biofilm can remain inside channels even when protocols are followed, creating patient safety risk. Variable and unverified Outcomes vary between individuals, shiŷs and workloads, with documentation covering only selected steps. THE SOLUTION The CORIS System automates and verifies the cleaning step A new benchmark in efficacy Delivers the physical friction required to remove soil and biofilm from narrow, branched and unbrushable channels. Engineered for consistency Standardises a critical step, reducing variability and supporting repeatable outcomes across every site. Traceable every cycle Captures validated cleaning parameters for each cycle, supporting verification and audit readiness. CORIS automates the one step in endoscope reprocessing that has remained manual, variable and unverified. Protects reprocessing teams Designed to reduce physical burden and exposure to chemicals and infectious materials via an automated, closed system workflow. Smarter Workflows Minimises labour-intensive manual steps, helping teams to focus on quality, compliance and other essential tasks. 23
Page 24
Large CORIS recurring revenue opportunity Capital, consumables and service compound as the installed base grows, leveraging the same annuity model as trophon. CAPITAL & ACCESSORIES 3-5X TROPHON capital price Mix of capital sales and other selling models. UTILISATION ~10 cycles per device per day High volume sites may have 3-4 units in Central Sterile Department. CONSUMABLES 4-6X TROPHON price per cycle Price will vary based on purchase model & market. SERVICE ~80% aźachment rate Customer opt-in, expected to be high post 1 year warranty. Note: Indicative metrics are early stage estimates, subject to change as commercial experience builds. procedural TAM1 across key regions >2M AUSTRALIA >5M UNITED KINGDOM & IRELAND >34M UNITED STATES procedure opportunity procedure opportunity procedure opportunity FY27 launch markets 24
Page 25
25
Page 26
UK CMR site feedback highlights strong workflow, usability and confidence in routine adoption OVERALL RESULT / 5 average statement score positive on routine adoption Workflow & capacity 4.65 / 5 95% positive • Reduced hands-on manual cleaning • Staff time can be redirected • Smoother, more predictable workflow • Helps manage peaks in endoscope demand Usability & workforce 5.00 / 5 100% positive • Easy to learn and follow • High confidence running a CORIS cycle • Reduces demanding, repetitive activity • Improves day-to-day working experience Consistency, quality & adoption 4.95 / 5 99.9% positive • More consistent than manual cleaning alone • Confidence that required steps are completed • Fits practically within the department • Strong support for routine adoption The CORIS System is delivering a consistently positive staff experience 26Survey of the 6 CORIS CMR site users.
Page 27
UK & Ireland CORIS launch Manchester Science & Industry Museum 27
Page 28
® Medical & Scientific category
Page 29
THE NANOSONICS VISION A multi-plaŹorm leader in automated infection prevention Building on trophon’s success to deliver the next phase of growth in automated infection prevention. trophon’s proven franchise and continuing growth to redefine endoscope reprocessing globally the porŹolio and geographic reach with discipline Build from Scale CORIS Expand 29
Page 30
30
Page 31
To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Ms Sarah Butler, who was appointed as a Director by the Board on 20 January 2026 and retires as a Director in accordance with the Constitution and ASX Listing Rule 14.4 and, being eligible for election (and offering her self for election), be elected as a Director. Sarah Butler FAICD Independent Non-executive Director Election of a Director, Ms Sarah Butler 31
Page 32
To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Dr Larry Marshall, who retires as a Director by rotation in accordance with the Constitution and ASX Listing Rule 14.4 and, being eligible for re-election (and offering himself for re-election), be re-elected as a Director. Larry Marshall BSc (Hons), PhD, FAICD, FTSE, FAIP, Federation Fellow Independent Non-executive Director Re-election of a Director, Dr Larry Marshall 32
Page 33
To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Dr Tracey Baźen, who retires as a Director by rotation in accordance with the Constitution and ASX Listing Rule 14.4 and, being eligible for re-election (and offering herself for re-election), be re-elected as a Director. Tracey Baźen MBBS, MBA (Harvard), FAICD, MHA, FRACMA Independent Non-executive Director Re-election of a Director, Dr Tracey Baźen 33
Page 34
To consider and, if thought fit, to pass the following advisory, non-binding resolution (in accordance with section 250R(3) of the Corporations Act) as an ordinary resolution: That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the financial year ended 30 June 2026 (as contained in the Directors’ Report) be adopted. Adoption of Remuneration Report 34
Page 35
To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That approval be given under and for the purpose of ASX Listing Rule 10. 14 and for all other purposes for the issue of 70,833 Service Rights to Nanosonics’ Chief Executive Officer and President, Mr Michael Kavanagh, under the Nanosonics Equity Plan in respect of Mr Kavanagh’s FY26 STI, on the terms and conditions summarised in the Explanatory Notes accompanying this Notice of Meeting and the Nanosonics Equity Plan Rules (as amended from time-to-time). Issue of 70,833 Service Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s 2026 Short Term Incentive grant (FY26 STI) and under the Nanosonics Equity Plan 35
Page 36
Resolution 6To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That approval be given under and for the purpose of ASX Listing Rule 10. 14 and for all other purposes for the issue of 625,363 Performance Rights to Nanosonics’ Chief Executive Officer and President, Mr Michael Kavanagh, under the Nanosonics Equity Plan in respect of Mr Kavanagh’s FY27 LTI, on the terms and conditions summarised in the Explanatory Notes accompanying this Notice of Meeting and he Nanosonics Equity Plan Rules (as amended from time-to-time). Issue of 625,363 Performance Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s FY27 Long-Term Incentive grant (FY27 LTI) and under the Nanosonics Equity Plan 36
Page 37
Resolution 7To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That, for the purpose of ASX Listing Rule 7 .2 (Exception 13) and for all other purposes, the Nanosonics Equity Plan (the terms and conditions of which are summarised in the Explanatory Notes accompanying this Notice of Meeting), and the issue of securities under the Nanosonics Equity Plan as an exception to ASX Listing Rule 7. 1 (including the maximum number of equity securities proposed to be issued under the Nanosonics Equity Plan within the 3-year period commencing on the date of the passing of this Resolution) as described in the Explanatory Notes accompanying this Notice of Meeting, be approved. Approval of the Nanosonics Equity Plan
Page 38
To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That, for the purposes of clauses 22. 1 and 22.8 of the Company’s Constitution and ASX Listing Rule 10. 17 (and for all other purposes), the maximum aggregate Remuneration (including directors’ fees specified in ASX Listing Rule 10. 17) that may be provided to or for the benefit of the Non-Executive Directors in any financial year of the Company be increased by $400,000 from $1,200,000 to $1,600,000. Increase in maximum aggregate Non-Executive Directors’ Remuneration 38
Page 39
How to ask a question •To ask a wriźen question, select the Q & A icon. •Select the topic your question relates to from the drop-down list. •Type your question in the text box and press the send icon. •To ask a verbal question follow the instructions below the broadcast window. 39
Page 40
How to vote •When the poll is open, select the vote icon at the top of the screen •To vote, select either For, Against or Abstain •You will see a vote confirmation •To change or cancel your vote “click here to change your vote” at any time until the poll is closed 40
Page 41
How to ask a question •To ask a wriźen question, select the Q & A icon. •Select the topic your question relates to from the drop-down list. •Type your question in the text box and press the send icon. •To ask a verbal question follow the instructions below the broadcast window. 41
Page 42
Nanosonics Limited 7-11 Talavera Road Macquarie Park, NSW 2113 Australia T +61 2 8063 1600 E info@nanosonics.com.au www.nanosonics.com.au ABN 11 095 076 896 Thank you
Page 43
Disclaimer 43 This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject maźer covered in it. The information in this presentation, whether wriźen or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation. Certain information may relate to protected intellectual property rights owned by Nanosonics Limited (Nanosonics) and its subsidiaries (together the Group). While due care has been taken in compiling the information based on the information available to Nanosonics at the date of this presentation material, neither Nanosonics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement or estimate by any person (including Nanosonics). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Nanosonics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Group since the date of these materials. trophon®, CORIS® and Nanosonics Connect® are registered trade marks of Nanosonics Limited.